

Our Ref: 320/2020  
December 2020

## Re: Your request made under the Freedom of Information Act 2000

---

Dear Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust,

I am analysing the usage of antiretroviral therapies. Could you please answer the following four questions?

1) How many patients were treated (for any condition) in the latest 6-month period with the following drugs:

- Juluca (rilpivirine/dolutegravir) **0**
- Dovato (lamivudine/dolutegravir) **4**
- Triumeq (abacavir/lamivudine/dolutegravir) **55**
- Tivicay (dolutegravir) **54**
- Isentress (raltegravir) **163**
- Biktarvy (TAF/emtricitabine/bictegravir) **1**
- Genvoya (TAF/emtricitabine/elvitegravir/cobisistat) **7**
- Symtuza (TAF/emtricitabine/darunavir/cobisistat) **17**
- Odefsey (TAF/emtricitabine/rilpivirine) **7**
- Descovy (TAF/emtricitabine) **97**
- Truvada or generic TDF/emtricitabine **31**

2) How many patients received any antiretroviral (ART) therapy for HIV treatment (excluding pre-exposure prophylaxis):

- for the latest 6-month period **327**
- for the 6 months from July-December 2019 **336**

3) How many patients were treated in the latest 6-months period with Truvada or generic TDF/emtricitabine for:

- HIV treatment **31**
- Pre-exposure prophylaxis (PrEP) **Unknown supplied as pre-labelled packs**

4) How many packs of Truvada or generic TDF/emtricitabine were dispensed in latest 6-month period for:

- HIV treatment **163**
- Pre-exposure prophylaxis (PrEP) **21**